Quest Diagnostics (NYSE: DGX) is the largest clinical laboratory company in the United States, providing diagnostic testing, information, and services. Through its Quest Diagnostics Ventures arm, the company makes strategic venture investments in early- to growth-stage healthcare and diagnostics startups.
38% of their portfolio is in Healthcare. Their most common stage is series-b (50% of deals). Average disclosed round size is $74.2M (across 7 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| PPreciseDx | Series B | $20.7M | Aug 2024 |
 PreciseDx | Series B | $20.7M | Aug 2024 |
 Freenome | Growth | $254M | Feb 2024 |
 UNIVERSAL DIAGNOSTICS, S.A. | Series B | $70M | Jan 2023 |
 SomaLogic | Series A | $121M | Jan 2020 |
| SomaLogic | Unknown | $16.5M | Jan 2015 |
| SomaLogic | Unknown | $16.5M | Jan 2014 |
| GGenomic Vision | Series B | — | — |
Top Co-Investors
Eventide Asset Management3 shared
Novartis Venture Fund3 shared
T. Rowe Price2 shared
Labcorp2 shared
Pura Vida Investments1 shared
DCVC1 shared
Roche Venture Fund1 shared
Cormorant Asset Management1 shared
Section 321 shared
Sands Capital1 shared
Polaris Partners1 shared
Perceptive Advisors1 shared
ArrowMark Partners1 shared
Bain Capital Life Sciences1 shared
Squarepoint Capital1 shared
RA Capital Management1 shared
Agilent Technologies1 shared
IBM Ventures1 shared
Last updated: 27 September 2026